Abstract 12904: Ticagrelor Removal From Human Blood

Background: In acute coronary events, ticagrelor is recommended to be loaded prior to cardiac catheterization. In the PLATO study the rate of severe bleeding on ticagrelor in patients who needed urgent bypass graft surgery was high but similar for ticagrelor and clopidogrel. The reversible binding mode of action of ticagrelor onto the P2Y12 receptor provides an opportunity for drug removal not possible for the thienopyridines (clopidogrel and prasugrel) which are all irreversibly binding to P2Y12. Objective: Our goal was to devise an efficient method for ticagrelor removal from blood. Methods: Ticagrelor removal was measured in two sets of experiments. The first set was performed in a first-pass manner and used as drug vehicle bovine serum albumin (BSA) solution (0.4% and 4%), while the second set employed in three experiments blood either bought from BioreclamationIVT (older than 24 hours) or freshly collected from a healthy volunteer and mixed with ticagrelor at a concentration of approximately 5.1 ug/m...